Growth Hormone Axis 7/6/2026

CJC-1295 With DAC + Ipamorelin: Extended Half-Life GHRH-GHRP Research

This blend combines an extended-half-life GHRH analog bearing a Drug Affinity Complex with a selective ghrelin-receptor agonist, enabling preclinical study of sustained dual-pathway GH-axis signaling.

CJC-1295 With DAC combined with Ipamorelin is a research blend that pairs an extended-half-life growth-hormone-releasing hormone (GHRH) analog with a selective growth-hormone-releasing peptide (GHRP). Its defining feature is the Drug Affinity Complex (DAC) carried by the CJC-1295 component, which markedly prolongs the molecule's stability compared with the No-DAC form.

The material is described here purely as an in-vitro and preclinical research tool. It is not for human or animal use, and no dosing, administration route, or therapeutic guidance is provided or implied.

Overview

CJC-1295 is a modified GHRH analog engineered for enhanced durability. The "With DAC" version incorporates a Drug Affinity Complex, a chemical moiety that binds covalently to serum albumin in model systems. Because albumin is a long-lived carrier protein, this attachment shields the peptide from rapid enzymatic clearance and dramatically extends its effective half-life relative to the No-DAC variant. Ipamorelin, the partner peptide, is a selective ghrelin-receptor (GHS-R1a) agonist.

The combination gives researchers a tool for studying sustained GHRH-receptor engagement alongside selective ghrelin-receptor activation, contrasting with the transient signaling profile of the No-DAC blend.

Mechanism of Action

The two components act on distinct but convergent receptor systems. CJC-1295 With DAC engages the GHRH receptor, a Gs-coupled receptor that raises intracellular cyclic AMP in model systems. Ipamorelin engages the ghrelin receptor, a Gq-coupled receptor that mobilizes intracellular calcium through the phospholipase-C pathway. As with other GHRH-plus-GHRP pairings, simultaneous engagement of these two cascades has been observed in preclinical research to produce responses greater than either agonist alone.

The key mechanistic distinction lies in the DAC. By binding albumin, the DAC-bearing GHRH analog maintains a more persistent presence in experimental systems, producing prolonged GHRH-receptor exposure rather than a brief pulse. Researchers studying somatotroph signaling have examined how this extended, more continuous GHRH signal interacts with the pulsatile ghrelin-receptor input from Ipamorelin, and how the combination influences the GH/IGF-1 axis under sustained-agonism conditions.

Primary Research Areas

Documented research directions for the DAC-bearing blend include:

Half-life and stability science, using the DAC as a case study in albumin-binding strategies that extend peptide durability

Sustained dual-pathway signaling, examining how prolonged GHRH-receptor activation combines with selective ghrelin-receptor agonism in somatotroph models

Comparative pharmacology between the With-DAC and No-DAC forms to isolate the effect of signaling duration

GH/IGF-1 axis regulation, including how sustained agonism interacts with somatostatin and IGF-1 feedback in model systems

What Preclinical Studies Explore

In preclinical settings, the blend is applied to cultured pituitary cells and related in-vitro platforms to study the consequences of extended GHRH-receptor engagement. Investigators compare the temporal profile of DAC and No-DAC variants, evaluate whether prolonged signaling alters receptor desensitization, and characterize how the sustained GHRH arm combines with the calcium-driven ghrelin-receptor arm. Because these peptides have been investigated for their effects on the GH/IGF-1 axis in preclinical models, the DAC blend is especially useful for studies that require a durable, long-acting GHRH stimulus.

Side-by-side comparison with the No-DAC blend is a common experimental strategy: holding the Ipamorelin component constant while switching between DAC and No-DAC GHRH analogs lets researchers attribute observed differences specifically to signaling duration.

Handling in the Lab

Blended peptides are usually supplied as a co-lyophilized powder. General good-practice handling for research use includes:

Storing the lyophilized blend cold, following supplier guidance, to protect both components

Reconstituting with a sterile diluent such as bacteriostatic water for in-vitro working solutions

Keeping solutions protected from light and limiting freeze-thaw cycles that degrade peptides

Aliquoting reconstituted material to maintain a consistent component ratio across experiments

Standard laboratory safety procedures and institutional guidelines for research reagents should be observed throughout.

Research Context

The CJC-1295 With DAC plus Ipamorelin blend occupies an important place in GH-axis research because it lets investigators study sustained, dual-pathway stimulation of somatotroph cells. The Drug Affinity Complex is what sets it apart: by extending the GHRH analog's half-life through albumin binding, it produces a more continuous signaling profile than the short-acting No-DAC form, while Ipamorelin contributes selective ghrelin-receptor activation. Together they help researchers dissect how signal duration and pathway synergy shape the GH/IGF-1 axis in model systems. As with all materials described here, this blend is intended solely for in-vitro laboratory research and is not for use in humans or animals.

Research Use Only

This article is provided for informational and educational purposes only. All products referenced are intended strictly for in-vitro research use and are not for human or animal consumption. These statements have not been evaluated by the FDA.